AVLN Avalyn Pharma Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1540171 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets7.3%
Debt / equity0.04x
Current ratio25.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $25.49M | $24.73M | $22.89M | $22.09M | $17.88M | $15.32M |
| SG&A expense | $7.60M | $6.56M | $5.02M | $3.23M | $3.90M | $3.40M |
| Operating income | -$33.09M | -$31.29M | -$27.91M | -$25.32M | -$21.78M | -$18.72M |
| Interest expense | $277,000 | $272,000 | $98,000 | $1,000 | $0 | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$29.66M | -$28.93M | -$26.87M | -$23.58M | -$20.19M | -$17.50M |
| EBITDA | -$32.99M | -$31.18M | -$27.85M | -$25.31M | -$21.77M | -$18.71M |
| EPS (basic) | -0.67 | -0.98 | -21.83 | -20.34 | -17.63 | -63.24 |
| EPS (diluted) | -0.67 | -0.98 | -21.83 | -20.34 | -17.63 | -63.24 |
| Weighted avg. shares (diluted) | 44.35M | 29.65M | 1.23M | 1.16M | 1.15M | 276,792 |
| Balance sheet | ||||||
| Cash & equivalents | $145.42M | $264.20M | $92.31M | $27.57M | $61.30M | $28.80M |
| Short-term investments | $182.03M | $88.23M | $30.82M | — | — | — |
| Current assets | $333.71M | $357.99M | $129.99M | — | — | — |
| PP&E, net | $1.17M | $1.21M | $1.26M | — | — | — |
| Total assets | $399.30M | $425.45M | $135.66M | — | — | — |
| Current liabilities | $12.96M | $10.81M | $11.79M | — | — | — |
| Long-term debt | $14.82M | $14.80M | $14.81M | — | — | — |
| Total debt | $14.82M | $14.80M | $14.81M | — | — | — |
| Total liabilities | $29.05M | $27.10M | $27.69M | — | — | — |
| Shareholders' equity | $370.25M | $398.35M | -$264.25M | -$215.56M | -$194.39M | -$191.57M |
| Net debt | -$130.61M | -$249.40M | -$77.50M | — | — | — |
| Shares outstanding | 44.39M | 44.33M | 1.23M | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$26.27M | -$26.08M | -$29.89M | -$17.31M | -$20.70M | -$19.27M |
| Capital expenditure | $72,000 | $269,000 | $318,000 | $84,000 | $0 | $8,000 |
| Free cash flow | -$26.34M | -$26.34M | -$30.21M | -$17.39M | -$20.70M | -$19.28M |
| Investing cash flow | -$91.77M | -$118.71M | $55.02M | -$26.32M | -$36.69M | $24.12M |
| Financing cash flow | -$733,000 | $316.67M | $14.86M | $9.90M | $89.88M | $0 |
| Depreciation & amortization | $104,400 | $110,000 | $63,000 | $9,000 | $9,000 | $10,000 |
| Stock-based compensation | $3.10M | $2.79M | $1.19M | $725,000 | $1.13M | $543,000 |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.